Hadassah

Hadassah Clinical Trial Reveals Safety and Efficacy of Stem Cell Technology in Treating ALS

Wednesday, Feb 15 2012

"This may represent the biggest hope in the field of degenerative diseases like ALS," Prof. Dimitrios Karussis, head of the Hadassah University Medical Center's Multiple Sclerosis Center, said about the clinical trial just completed at Hadassah where stem cells were used to treat Amyotrophic Lateral Sclerosis (ALS).

Even though this was a trial to determine the safety of the technology, early clinical follow up of the patients demonstrated an improvement in breathing and swallowing ability as well as in muscular power. "I am very excited about the safety results, as well as the indications of efficacy," Prof. Karussis said. The initial patients who were treated with BrainStorm Cell Therapeutics' NurOwn™ stem cell technology experienced no significant side effects in this Phase I/II clinical trial. As a result, Hadassah's ethics and safety committee has now granted BrainStorm approval to proceed with treating additional patients.

NurOwn™ technology processes adult human stem cells that are present in bone marrow and are capable of self-renewal and differentiation into many other cell types. A progressive neurodegenerative disease, ALS, often referred to as Lou Gehrig's disease, affects nerve cells in the brain and the spinal cord. With this technology, the bone marrow cells are induced to differentiate into cells capable of releasing neurotrophic factors which can help ALS patients. According to the ALS Association, approximately 5,600 people in the United States are diagnosed with ALS each year and it is estimated that as many as 30,000 Americans may have the disease at any given time.

The study, led by Prof. Karussis, is being conducted in conjunction with a scientific team from BrainStorm.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Jan 11 2018

Hadassah’s Heart Institute: Innovation at the Forefront

Prof. Chaim Lotan, head of the Hadassah Medical Organization’s Heart Institute, has made it a personal objective to foster innovation in cardiovascular technology.

READ MORE ›
alt_text

Thursday, Jan 11 2018

Medical Clown Nehama’s Blog, Chapter Five: Out of Love

“I met Masha in the surgery waiting room at Hadassah Hospital Ein Kerem,” says Medical Clown Shira, as she proceeds to convey this story: Masha is a three-year-old girl who lives in Russia. Every three months, she comes to Hadassah for an oncological examination under full anesthesia.

READ MORE ›
alt_text

Wednesday, Jan 10 2018

Drug Company Collaborates with Hadassah Liver Specialist in Fighting Liver Disease

Dr. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit, in its Institute of Gastroenterology and Liver Diseases, is collaborating with Can-Fite BioPharma Ltd. to explore further the healing effects of a new drug that has proven in preclinical studies to mitigate inflammatory diseases of the liver, such as NASH (non-alcoholic steatohepatitis).

READ MORE ›
alt_text

Wednesday, Jan 10 2018

Bedridden Teen Walks Again, Thanks to First-in-Israel Complex Spinal Surgery at Hadassah

Yusef Rabaya, age 19, spent most of his life in bed at home in Jenin. Born with cerebral palsy (CP), he could sit only if he was propped up. Standing was excruciating and dangerous--and could cause permanent paralysis.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More